Enjoy complimentary customisation on priority with our Enterprise License!
This pipeline analysis report provides detailed insights into the clinical trial landscape of malaria therapeutics, including molecules at the pre-clinical and discovery stage. This malaria diagnostics market report also covers information about the therapeutic assessment of the pipeline molecules based on therapies employed, route of administration, target, mechanism of action (MoA), and therapeutic modalities. Also, the report provides an analysis of the companies currently involved in the development of pipeline molecules for malaria including Astellas Pharma Inc., Bharat Biotech Ltd., Carna Biosciences Inc., Eisai Co. Ltd., Lipotek Pty Ltd., Merck KGaA, Novartis AG, Nurex Srl, Sanaria Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and VLP Therapeutics.
It has been observed that children under five years of age are the most vulnerable group affected by malaria. Children with severe malaria very often develop one or more symptoms, including severe anemia, respiratory distress in relation to metabolic acidosis, or cerebral malaria. On the other hand, multi-organ failure is very common in adults with malaria. Although in malaria-endemic areas, people may develop partial immunity, allowing asymptomatic infections to occur, the demand for effective combination and intravenous therapeutics is increasing. The drugs are formulated to eliminate Plasmodium parasites, which causes the disease. Among the several Plasmodium species, P. falciparum is the most lethal if left untreated. Globally, the incidence and prevalence of malaria are decreasing every year. However, The WHO African Region continues to carry a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths.
Most of the molecules in the pipeline are being developed for monotherapy and oral route of administration. Over 35% of the molecules in the pipeline are currently in the discovery and pre-clinical stages. In addition to the active molecules, there are also a number of pipeline products that have been either discontinued from development or are currently dormant.
This malaria diagnostics market report provides a detailed analysis of companies that are involved in the development of molecules for the treatment of malaria. The report provides information on the number of molecules currently developed by companies and the various stages of these molecules. The report also covers details on the collaboration of these companies with institutions to utilize the available technologies for further development and commercialization of molecules.
Some of the companies covered in this pipeline analysis report include -
The intramuscular route of administration (RoA) has more rapid onset action compared with oral administration. It is also more effective than intravenous molecules as a few drugs irritate the veins, and there are instances wherein the vein cannot be located. However, most of the molecules that are currently in the pipeline are being developed for oral administration.
Monotherapy uses a single drug to treat a disorder. Most of the molecules that are currently in the pipeline to treat malaria are being developed as monotherapy drugs.
We can help! Our analysts can customize this report to meet your requirements.Get in touch
PART 01: Executive summary
PART 02: Scope
PART 03: Disease overview
PART 05: Drug development landscape
PART 06: Drug development strategies
PART 07: Recruitment strategies
PART 08: Key companies
PART 09: Astellas Pharma, Inc.
PART 10: Bharat Biotech Ltd.
PART 11: Carna Biosciences, Inc.
1.18Overview
PART 12: Eisai Co. Ltd.
PART 13: Lipotek Pty Ltd.
PART 14: Merck KGaA
PART 15: Novartis AG
PART 16: Nurex Srl
PART 17: Sanaria, Inc.
PART 18: Sanofi
PART 19: Takeda Pharmaceutical Co. Ltd.
PART 20: VLP Therapeutics
PART 21: Dormant molecules
PART 22: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.